3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
5
Thoracic
4
Genitourinary
2
Gastrointestinal
2
Dermatologic
2
Gynecologic
1
Conditions
Colorectal Neoplasms
29
Carcinoma, Non-Small-Cell Lung
17
Pancreatic Neoplasms
12
Neoplasm Metastasis
9
Stomach Neoplasms
7
Lung Neoplasms
7
Rectal Neoplasms
6
Neoplasms
6
Melanoma
6
Esophageal Neoplasms
6
Colonic Neoplasms
6
Ovarian Neoplasms
4
Gastrointestinal Neoplasms
4
Breast Neoplasms
4
Prostatic Neoplasms
3
Head and Neck Neoplasms
3
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms by Site
2
Liver Neoplasms
2
Hypopharyngeal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Pancreatic Ductal
2
Biliary Tract Neoplasms
2
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Diseases
1
Interventions
pembrolizumab
39
Nivolumab
15
Gemcitabine
8
spartalizumab
7
atezolizumab
7
Carboplatin
7
Cyclophosphamide
6
130-nm albumin-bound paclitaxel
6
durvalumab
5
Cisplatin
5
Bevacizumab
5
fludarabine
4
budigalimab
4
Paclitaxel
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Fluorouracil
4
Cetuximab
4
Albumin-Bound Paclitaxel
4
tislelizumab
3
lenvatinib
3
cemiplimab
3
avelumab
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Irinotecan
3
HMPL-013
3
Fulvestrant
3
Docetaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Pemetrexed
×
Gastrointestinal
×
Clear all
NCT03267316
2024-08-22
CANFOUR
Cantargia AB
Phase 1/2
Completed
167 enrolled
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts